PT  - JOURNAL ARTICLE
AU  - Christophe Dooms
AU  - Inge Hantson
AU  - Liesbet Vliegen
AU  - Eric Verbeken
AU  - Peter Vandenberghe
AU  - Johan Vansteenkiste
TI  - Feasibility of EGFR mutation testing on EBUS-TBNA and bronchial biopsy samples obtained during routine practice
DP  - 2012 Sep 01
TA  - European Respiratory Journal
PG  - P767
VI  - 40
IP  - Suppl 56
4099  - http://erj.ersjournals.com/content/40/Suppl_56/P767.short
4100  - http://erj.ersjournals.com/content/40/Suppl_56/P767.full
SO  - Eur Respir J2012 Sep 01; 40
AB  - Introduction.Approximately 80% of NSCLC present with advanced disease, in whom the diagnosis is often based on small samples obtained during bronchoscopy.Aims.We aimed to evaluate the performance of bronchoscopic small tissue samples: (1) the percentage of tumour cells and quantity of DNA extracted; (2) the performance of EGFR mutation testing; (3) their feasibility compared to surgical samples.Methods.Between Sep 2010 and Dec 2012, we screened advanced stage non-squamous histology for EGFR mutations using Therascreen. All diagnostic bronchial biopsies (n=130; 4 biopsies per patient) and EBUS-TBNA samples (n=81; 4 needle aspirations brought in cell block), as well as surgical samples (n=67) were retrieved.Results.The median percentage tumour cells and quantity of DNA extracted was significantly higher in surgical vs bronchoscopic samples (80% vs 30% and 2.3µg vs 1.6μg, P<0.0001); no statistically significant difference was observed between EBUS-TBNA and bronchial biopsies.View this table:Table 1. Tissue sample performance characteristicsAlthough 25% of bronchoscopic samples had <10% tumour cells, an amount of DNA extracted <200ng and poor DNA quality (Cp>35) were observed in 1%.Conclusions.Bronchoscopic samples result in accurate EGFR mutation analysis in routine practice, provided a sufficient samples are taken.